Antares Pharma Shares Close Up 4.1%, Up Another 6.1% After Hours On News Its Partner, Teva, Received FDA Approval For Its Generic Epinephrine, For Which Antares Has the Exclusive License to Market In The U.S.
Benzinga Newsdesk